drugset

drugset / Trial / NCT03952806

Study of BHV-3241 in Participants With Multiple System Atrophy

NCT03952806 ↗

Phase 3 Completed 421 enrolled Biohaven Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy

Timeline

Start: 2019-07-29
Primary completion: 2021-07-29
Completion: 2022-06-30

Outcome

Missed primary endpoint

registry p = 0.4656; Least Square mean difference 0.35 (95% CI -0.60 to 1.30) NCT03952806 ↗

Publications

Schmahmann JD, Pierce S, MacMore J, L'Italien GJ. Development and Validation of a Patient-Reported Outcome Measure of Ataxia. Mov Disord. 2021 Oct;36(10):2367-2377. doi: 10.1002/mds.28670. Epub 2021 Jun 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Verdiperstat	Small molecule	600 mg	Oral

Indications